KR20020022868A - 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법 - Google Patents
유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법 Download PDFInfo
- Publication number
- KR20020022868A KR20020022868A KR1020000055399A KR20000055399A KR20020022868A KR 20020022868 A KR20020022868 A KR 20020022868A KR 1020000055399 A KR1020000055399 A KR 1020000055399A KR 20000055399 A KR20000055399 A KR 20000055399A KR 20020022868 A KR20020022868 A KR 20020022868A
- Authority
- KR
- South Korea
- Prior art keywords
- cholesterol
- lipid
- dna
- cell
- cationic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
- 하기 화학식 1로 표시되는 양이온성 지질.화학식 1상기 식에서 y 및 z는 서로 같거나 다른 1 내지 20 사이의 자연수이고; R1∼R5는 서로 같거나 다른 수소, 탄소수 1∼10 사이의 알킬 또는 하이드록시 알킬기, 또는 탄소수 7∼11 사이의 아릴 또는 알알킬기이며; R6은 콜레스테롤 라디칼이고; X는 약학적으로 허용 가능한 할로겐 음이온이다.
- 제1항에 있어서, 상기 X는 Br, Cl 또는 I인 것을 특징으로 하는 양이온성 지질.
- 용매 존재하에서, 콜레스테롤 옥시 유도체에 질소원자를 포함하는 유기염기와 하이드록시 알킬 할라이드를 적가하여 하기 화학식 2로 표시되는 콜레스테롤 옥시 알킬렌 할라이드를 얻은 다음, 이를 용매존재하에서 수소, 또는 한 개 이상의알킬기 또는 하이드록시 알킬기가 치환된 디아민과 반응시킨후, 수소 또는 하이드록시 알킬 또는 알킬 할라이드와 반응시켜 디암모늄염을 생성시키는 것을 특징으로 하는 하기 화학식 1로 표시되는 양이온성 지질의 제조방법.화학식 2X-(CH2)zO-R6화학식 1상기 식에서 y 및 z는 서로 같거나 다른 1 내지 20 사이의 자연수이고; R1∼R5는 서로 같거나 다른 수소, 탄소수 1∼10 사이의 알킬 또는 하이드록시 알킬기, 또는 탄소수 7∼11 사이의 아릴 또는 알알킬기이며; R6은 콜레스테롤 라디칼이고; X는 약학적으로 허용 가능한 할로겐 음이온이다.
- 제3항에 있어서, 상기 콜레스테롤 옥시 유도체는 콜레스테롤 메실레이트인 것을 특징으로 하는 양이온성 지질의 제조방법.
- 제3항에 있어서, 상기 유기염기는 피리딘이고, 상기 하이드록시 알킬 할라이드는 2-브로모에탄올이며, 상기 디아민은 테트라메틸에틸렌디아민인 것을 특징으로 하는 양이온성 지질의 제조방법.
- (a) 다른 지질과 복합체를 형성하는 유효량의 제1항에 따른 양이온성 지질을 포함하는 조성물과 음이온성 분자물질을 접촉시켜 지질 복합체를 형성시키는 단계; 및(b) 상기 지질 복합체와 세포를 접촉시키는 단계를 포함하는 것을 특징으로 하는 세포에 음이온성 분자물질을 전달하는 방법.
- 제6항에 있어서, 상기 조성물이 하나 이상의 부가적인 지질을 포함하는 것을 특징으로 하는 세포에 음이온성 분자물질을 전달하는 방법.
- 제6항에 있어서, 상기 부가적인 지질인 DOPE, DOPC, PC 및 콜레스테롤로 이루어진 군으로부터 하나 또는 그 이상 선택됨을 특징으로 하는 세포에 음이온성 분자물질을 전달하는 방법.
- 제6항에 있어서, 상기 음이온성 분자물질은 DNA, RNA, 단백질, 펩타이드 또는 생물학적 활성 약물인 것을 특징으로 하는 세포에 음이온성 분자물질을 전달하는 방법.
- 제6항에 있어서, 상기 세포가 HeLaS 3, HepG 2, Hep 3B, NIH 3T3, CHRC 2 또는 COS 7인 것을 특징으로 하는 세포에 음이온성 분자물질을 전달하는 방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0055399A KR100373844B1 (ko) | 2000-09-21 | 2000-09-21 | 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0055399A KR100373844B1 (ko) | 2000-09-21 | 2000-09-21 | 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020022868A true KR20020022868A (ko) | 2002-03-28 |
KR100373844B1 KR100373844B1 (ko) | 2003-02-26 |
Family
ID=19689688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0055399A KR100373844B1 (ko) | 2000-09-21 | 2000-09-21 | 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100373844B1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009051451A3 (en) * | 2007-10-17 | 2009-06-04 | Korea Advanced Inst Sci & Tech | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
WO2017105138A1 (ko) * | 2015-12-18 | 2017-06-22 | 주식회사 삼양바이오팜 | 음이온성 약물을 함유하는 고분자 미셀의 제조방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
FR2727679B1 (fr) * | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
US5650096A (en) * | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5980935A (en) * | 1996-05-15 | 1999-11-09 | Kirpotin; Dmitri | Cationic lipids and methods of use therefor |
-
2000
- 2000-09-21 KR KR10-2000-0055399A patent/KR100373844B1/ko active IP Right Grant
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009051451A3 (en) * | 2007-10-17 | 2009-06-04 | Korea Advanced Inst Sci & Tech | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
WO2017105138A1 (ko) * | 2015-12-18 | 2017-06-22 | 주식회사 삼양바이오팜 | 음이온성 약물을 함유하는 고분자 미셀의 제조방법 |
AU2016372321B2 (en) * | 2015-12-18 | 2019-01-24 | Samyang Holdings Corporation | Method for preparing polymeric micelle containing anionic drug |
Also Published As
Publication number | Publication date |
---|---|
KR100373844B1 (ko) | 2003-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6271208B1 (en) | Process of making cationic lipid-nucleic acid complexes | |
US5851548A (en) | Liposomes containing cationic lipids and vitamin D | |
EP0656883B1 (en) | Cationic lipids | |
US6852334B1 (en) | Cationic peg-lipids and methods of use | |
JP4695075B2 (ja) | トランスフェクションで使用するためのスフィンゴ脂質ポリアルキルアミン抱合体 | |
US5739271A (en) | Thiocationic lipids | |
WO1997046223A1 (en) | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules | |
EP1328254A2 (en) | Lipid formulations for target delivery | |
US5711964A (en) | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D | |
MXPA02002899A (es) | Lipido cationico neutro para la administracion de acido nucleico y farmaco. | |
US6927213B2 (en) | Cationic cholesteryl derivatives containing cyclic polar groups | |
US6583131B2 (en) | Cationic cholesteryl derivatives containing cyclic polar groups | |
KR100373844B1 (ko) | 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법 | |
EP0747351A2 (en) | Thiocationic lipids, pharmaceutical compositions and methods of use thereof | |
KR100373845B1 (ko) | 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법 | |
KR100381512B1 (ko) | 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 용도 | |
US5759519A (en) | Method for the intracellular delivery of biomolecules using thiocationic lipids | |
US5756352A (en) | Thiocationic lipid-nucleic acid conjugates | |
Audrezet et al. | Novel cationic phosphonolipids agents for in vitro gene transfer to epithelial cell lines | |
AU715376C (en) | Novel cationic cholesteryl derivatives containing cyclic polar groups | |
US20050048108A1 (en) | Sulphur-containing amphiphilic agents for the transfer of biologically active molecules into cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130311 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20140211 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20151106 Year of fee payment: 13 |
|
R401 | Registration of restoration | ||
FPAY | Annual fee payment |
Payment date: 20160202 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20170207 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20180207 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20190129 Year of fee payment: 17 |